Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Immunotherapy

Combined immunotherapy—a new standard in metastatic melanoma?

Nature Reviews Clinical Oncology volume 12, pages 439–440 (2015)Cite this article

Subjects

The efficacy of immunotherapy in metastatic melanoma is established, with anti-CTLA-4 and anti-PD-1 antibody-based therapies providing unexpectedly high responses and prolonged survival. The combination of nivolumab and ipilimumab is now poised to become the new standard of care, based on a 61% response rate in a recent randomized extended phase I/II trial, confirmed by phase III data presented at ASCO 2015.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    Article  CAS  Google Scholar 

  2. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).

    Article  CAS  Google Scholar 

  3. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).

    Article  CAS  Google Scholar 

  4. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. https://dx.doi.org/10.1056/NEJMoa1503093.

  5. Das, R. et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194, 950–959 (2015).

    Article  CAS  Google Scholar 

  6. Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015).

    Article  Google Scholar 

  7. Chapman, P. B., D'Angelo, S. P. & Wolchok, J. D. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N. Engl. J. Med. 372, 2073–2074 (2015).

    Article  Google Scholar 

  8. Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. https://dx.doi.org/10.1200/JCO.2014.59.4358.

  9. Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013).

    Article  CAS  Google Scholar 

  10. Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. https://dx.doi.org/10.1056/NEJMoa1504030.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University Hospital of Schleswig-Holstein, Campus Kiel, Schittenhelmstrasse 7, Kiel, 24105, Germany

    Axel Hauschild

  2. Division of Dermatooncology, Department of Dermatology, University Medical Center, Liebermeisterstrasse 25, Tuebingen, 72074, Germany

    Claus Garbe

Authors
  1. Axel Hauschild
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claus Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Hauschild.

Ethics declarations

Competing interests

A.H. has consulted and receives honoraria for Amgen, BMS, Celgene, Merck Serono, MDS/Merck, Novartis, OncoSec and Roche Pharma. C.G. receives personal fees from Amgen and Novartis, and grants and personal fees from BMS, GSK, Merck, and Roche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hauschild, A., Garbe, C. Combined immunotherapy—a new standard in metastatic melanoma?. Nat Rev Clin Oncol 12, 439–440 (2015). https://doi.org/10.1038/nrclinonc.2015.118

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.118

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing